Over the past several decades, the treatment of rheumatoid arthritis (RA) has advanced
significantly, and clinical, structural, and functional remission are achievable therapeutic …

Objectives Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-
error and can be challenging due to a myriad of contributing factors. We aimed to identify …

Purpose of Review A subset of patients with rheumatoid arthritis (RA) who fail multiple
biologic therapies are deemed to have “difficult-to-treat”(D2T) RA. In 2021, a European …

Despite the improvement in treatment for people with RA,∼ 30% of patients remain
symptomatic in the presence of optimized medical therapy, described as having 'difficult-to …

Management of RA patients has significantly improved over the past decades. However, a
substantial proportion of patients is difficult-to-treat (D2T), remaining symptomatic after …

Objectives Most studies on difficult-to-treat rheumatoid arthritis (D2T RA) have focused on
established RA. Here, we analyse whether disease activity in the early stages of RA could …

Despite the significant progress in Rheumatoid Arthritis (RA) therapeutics, there are several
reports in the literature claiming that the size of unmet needs in RA is large. In the era before …

Factors influencing prognosis after administration of the last biologic or targeted synthetic
disease-modifying antirheumatic drug (b/tsDMARD) to patients with difficult-to-treat …

Difficult-to-treat rheumatoid arthritis (D2T RA) is a multifactorial condition in which disease
activity of RA persists despite consecutive treatment with biological or targeted synthetic …

The European Alliance of Associations for Rheumatology recently defined difficult to treat
(D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This …